Market cap data unavailable. We couldn't positively verify this ticker's market cap is under $500M. Verify independently before trading.
Nextel Medical Corp.
- Market Cap
- Unavailable
- Price
- $0.0044
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.33%
- Volume
- 1.1M
About
Nextel Medical Corp., a clinical stage biotechnology company, develops ways to exploit the therapeutic potential of exosomes for the field of oncology in the United States. The company was formerly known as Exousia Pro, Inc. and changed its name to Nextel Medical Corp. in April 2026. Nextel Medical Corp. was incorporated in 2010 and is based in Saint Petersburg, Florida.
Quick stats
Shares outstanding—
Computed float15.2M
Float / sharesUnknown
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001492448
Websitehttps://www.exousiapro.com
AI Summary
AI-generated1/14
minorneutralproduct launch
NexTel Medical Corp. Announces Next-Generation Wellness Product Line Incorporating FDA-Approved Pharmaceuticals
NexTel Medical Corp. announced plans to launch a wellness product line incorporating FDA-approved active pharmaceutical ingredients with non-invasive delivery formulations.
The company cites an estimated $7-$10 billion unregulated market for peptides and metabolic therapies, positioning its products as compliant alternatives to grey-market 'Research Use Only' compounds.
Commercial rollout is not scheduled until Q2 2027; the release contains no revenue, regulatory submission, or clinical data, so it is promotional rather than a material catalyst.
Red flags
- Product launch is ~9 months away with no commercial traction disclosed
- Wellness products incorporating FDA-approved APIs may face regulatory scrutiny; company conflates FDA-approved ingredients with product-level approval
- Micro-cap OTC issuer issuing promotional market-sizing claims via analyst estimates